New T2 drug from Sanofi-Aventis proving successful in trials

Sanofi-Aventis said that lixisenatide, an experimental Type 2 diabetes drug, has been very successful in a late stage trial at helping patients reduce their blood sugar levels and lose weight, according to a recent article from Reuters, as reported by Diabetes Newshound.

The study also found that the drug didn’t raise patients’ risk of hypoglycemia compared to a placebo.

The drug works by stimulating the pancreas to release extra insulin when blood sugar levels run too high. If the drug received FDA approval, it would compete against Victoza and Amylin from Novo Nordisk and Byetta from Eli Lilly.

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).
Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags